Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07027527Phase 1Active, not recruiting
- Sponsor
- Apogee Therapeutics
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Modality
- IgG Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of apg777 and APG990 in atopic dermatitis (AD) (2 arms), sponsored by Apogee Therapeutics. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events at 24 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
apg777APG990
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07027527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027527.